Ultraprecise Antigen 10-in-1 Pool Testing by Multiantibodies Transistor Assay
Ultraprecise Antigen 10-in-1 Pool Testing by Multiantibodies Transistor Assay
复制标题
通过多抗体晶体管检测进行超精密抗原 10 合 1 池测试
DOI：
10.1021/jacs.1c08598
复制
发表时间：
2021-12-01
影响因子：
15
通讯作者：
Wei, Dacheng
中科院分区：
文献类型：
--
作者：
Dai, Changhao;Guo, Mingquan;Wei, Dacheng
传染病的有效筛查需要快速、廉价和人群规模的检测。抗原库检测可提高检测率，缩短筛查时间，是一种有价值的疫情防控手段。然而，聚合酶链反应（PCR）的总体一致率（OPA）为二分之一到四分之三，阻碍了它成为超越金标准PCR的综合方法，特别是合并试验。在这里，多抗体晶体管检测开发的灵敏度和高精度的抗原池测试。多抗体捕获SARS-CoV-2刺突S1蛋白具有不同的配置，导致抗原结合亲和力低至0.34 fM。在人工唾液中的检测限达到3.5 × 10（-17）g mL（-1）SARS-CoV-2 spike S1蛋白，比现有的晶体管传感器低4-5个数量级。对60份鼻咽拭子进行PCR检测，结果与100%OPA相似，平均诊断时间为38.9s。由于其高精度的特点，一个便携式的集成平台，它实现了10合1混合筛选高检测通量。这项工作解决了长期存在的抗原池检测问题，使其成为未来精确诊断和全人群筛查COVID-19或其他流行病的宝贵工具。
Effective screening of infectious diseases requires a fast, cheap, and population-scale testing. Antigen pool testing can increase the test rate and shorten the screening time, thus being a valuable approach for epidemic prevention and control. However, the overall percent agreement (OPA) with polymerase chain reaction (PCR) is one-half to three-quarters, hampering it from being a comprehensive method, especially pool testing, beyond the gold- standard PCR. Here, a multiantibodies transistor assay is developed for sensitive and highly precise antigen pool testing. The multiantibodies capture SARS-CoV-2 spike S1 proteins with different configurations, resulting in an antigen-binding affinity down to 0.34 fM. The limit of detection reaches 3.5 x 10(-17) g mL(-1)SARS-CoV-2 spike S1 protein in artificial saliva, 4-5 orders of magnitude lower than existing transistor sensors. The testing of 60 nasopharyngeal swabs exhibits similar to 100% OPA with PCR within an average diagnoses time of 38.9 s. Owing to its highly precise feature, a portable integrated platform is fabricated, which achieves 10-in-1 pooled screening for high testing throughput. This work solves the long-standing problem of antigen pool testing, enabling it to be a valuable tool in precise diagnoses and population-wide screening of COVID-19 or other epidemics in the future.